{"id":1667708,"date":"2026-03-06T10:45:00","date_gmt":"2026-03-06T15:45:00","guid":{"rendered":"https:\/\/bugaluu.com\/news\/?p=1667708"},"modified":"2026-03-06T10:45:00","modified_gmt":"2026-03-06T15:45:00","slug":"the-us-leads-the-world-in-the-weight-loss-injection-boom","status":"publish","type":"post","link":"https:\/\/bugaluu.com\/news\/the-us-leads-the-world-in-the-weight-loss-injection-boom\/1667708\/","title":{"rendered":"The US Leads The World In The Weight-Loss Injection Boom"},"content":{"rendered":"<p><span class=\"field field--name-title field--type-string field--label-hidden\">The US Leads The World In The Weight-Loss Injection Boom<\/span><\/p>\n<div class=\"clearfix text-formatted field field--name-body field--type-text-with-summary field--label-hidden field__item\">\n<p><strong>Novo Nordisk\u2019s obesity-drug franchise has surged at a remarkable pace. <\/strong>In just four years, revenue from its weight-management treatments ballooned roughly tenfold &#8211; from about $1.3 billion in 2021 to approximately $12.4 billion in 2025. The growth has been fueled largely by Wegovy, the company\u2019s blockbuster weight-loss drug built around the active ingredient semaglutide and marketed as a once-weekly injection.<\/p>\n<p>Semaglutide itself was originally developed to treat type 2 diabetes and continues to be sold under the brand name Ozempic for that purpose. The primary difference between the two products lies in dosage. As <a href=\"https:\/\/www.statista.com\/chart\/amp\/35920\/weight-loss-drug-sales-by-novo-nordisk-in-the-us-and-the-rest-of-the-world\/\"><em>Statista<\/em><\/a>\u00a0notes, <strong>Wegovy is formulated at higher semaglutide levels for weight management, while Ozempic is designed for blood-sugar control in diabetic patients.<\/strong> In practice, however, Ozempic has frequently been prescribed off-label for weight loss &#8211; a practice that is restricted or prohibited in several European Union countries.<\/p>\n<p>Regardless of branding, <strong>the United States has emerged as Novo Nordisk\u2019s most important market.<\/strong> According to the company\u2019s 2025 annual report, the U.S. accounts for the overwhelming share of sales for both Ozempic and Wegovy. For drugs marketed specifically for weight loss, more than 60% of global revenue comes from the American market &#8211; a reflection of both the country\u2019s large pharmaceutical sector and its high obesity rates, which have helped make the U.S. the epicenter of the global GLP-1 boom.<\/p>\n<p><a href=\"https:\/\/cms.zerohedge.com\/s3\/files\/inline-images\/35920.jpeg_80.jpg?itok=z_eGpUIX\"><\/a><\/p>\n<\/div>\n<p>      <span class=\"field field--name-uid field--type-entity-reference field--label-hidden\"><a title=\"View user profile.\" href=\"https:\/\/cms.zerohedge.com\/users\/tyler-durden\" class=\"username\">Tyler Durden<\/a><\/span><br \/>\n<span class=\"field field--name-created field--type-created field--label-hidden\">Fri, 03\/06\/2026 &#8211; 05:45<\/span><\/p>\n<p>\u200b<a href=\"https:\/\/www.zerohedge.com\/medical\/us-leads-world-weight-loss-injection-boom\" target=\"_blank\" class=\"\">https:\/\/www.zerohedge.com\/medical\/us-leads-world-weight-loss-injection-boom<\/a>\u00a0<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The US Leads The World In The Weight-Loss Injection Boom Novo Nordisk\u2019s obesity-drug franchise has surged at a remarkable pace. In just four years, revenue&#8230;<\/p>\n","protected":false},"author":0,"featured_media":1667709,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1667708","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","wpcat-1-id"],"_links":{"self":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts\/1667708","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/comments?post=1667708"}],"version-history":[{"count":1,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts\/1667708\/revisions"}],"predecessor-version":[{"id":1667731,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/posts\/1667708\/revisions\/1667731"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/media\/1667709"}],"wp:attachment":[{"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/media?parent=1667708"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/categories?post=1667708"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bugaluu.com\/news\/wp-json\/wp\/v2\/tags?post=1667708"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}